Montgomery County biopharmaceutical firm reducing workforce by 40% Email  Share  Share  Tweet Share Article Print Order Reprints
Enlarge
The antibiotic Xenleta is one of two products marketed by Fort Washington-based Nabriva.
NABRIVA
IN THIS ARTICLE
Biotech
Topic
Pharmaceuticals
Topic
Merck
Company
Ted Schroeder
Person
By John George  –  Senior Reporter, Philadelphia Business Journal
Nov 10, 2022
Listen to this article     3 min
Nabriva Therapeutics, a biopharmaceutical company with operations in Fort Washington and Ireland, said Thursday it is reducing its workforce by 40% and pivoting its focus to commercializing its skin and skin structure infections antibiotic while it explores “strategic options” for its future.
The company started the year with 73 employees, 38 of whom work in Montgomery County. The 40% reduction will result in about 29 jobs being eliminated.